Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

81°
- Benton, AR (72018)
  Today
  
  Mostly cloudy skies with showery rains and a possible rumble of thunder this afternoon. A few storms may be severe. High 81F. Winds SW at 10 to 15 mph. Chance of rain 100%..
  
  Tonight
  
  Scattered thunderstorms this evening followed by a few showers overnight. Low near 65F. Winds light and variable. Chance of rain 50%.
  
  Updated: May 19, 2026 @ 12:14 pm
- Full Forecast

- Site search

Home
News
- Local News
Sports
Obituaries
Multimedia
- Photo Galleries
- Videos
e-Edition
Classifieds
Archives
Readers Choice 2026
Community Calendar

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

799.08 +22.82 (+2.94%)

Streaming Delayed Price Updated: 1:05 PM EDT, May 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions

November 01, 2023

From argenx SE

Via GlobeNewswire

argenx to Present at Upcoming Investor Conferences

November 01, 2023

From argenx SE

Via GlobeNewswire

Argenx Comes Up With Big Sales Beat, Narrower-Than-Expected Losses ↗

October 31, 2023

The company sells Vyvgart, a treatment for generalized myasthenia gravis.

Via Investor's Business Daily

Topics Earnings

argenx Reports Third Quarter 2023 Financial Results and Provides Business Update

October 31, 2023

From argenx SE

Via GlobeNewswire

Earnings Outlook For argenx ↗

October 30, 2023

Via Benzinga

Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years ↗

October 19, 2023

Via Benzinga

Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years ↗

October 03, 2023

Via Benzinga

The Latest Analyst Ratings for argenx ↗

September 18, 2023

Via Benzinga

$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗

September 15, 2023

Via Benzinga

argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023

October 24, 2023

From argenx SE

Via GlobeNewswire

Stock Market Rally Attempt Underway; Micron, Nike, Amazon, Meta In Focus: Weekly Review ↗

September 29, 2023

But it's not a confirmed uptrend yet. Nike, Amazon and Meta were in focus.

Via Investor's Business Daily

What's Going On Pfizer's Subsidiary Biohaven Stock? ↗

September 27, 2023

Pfizer Inc's (NYSE: PFE) subsidiary Biohaven Ltd (NYSE: BHVN) released an

Via Benzinga

Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29% ↗

September 27, 2023

The companies hope by lowering immunoglobulin G, an antibody, that they can treat myriad autoimmune diseases.

Via Investor's Business Daily

Why Immunovant Stock Is Bolting Higher Today ↗

September 27, 2023

The company may have best-in-class autoimmune disease therapy under its roof.

Via The Motley Fool

What 20 Analyst Ratings Have To Say About argenx ↗

August 31, 2023

Via Benzinga

Here's How Much $1000 Invested In argenx 5 Years Ago Would Be Worth Today ↗

August 30, 2023

Via Benzinga

Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years ↗

August 10, 2023

Via Benzinga

Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering ↗

September 27, 2023

Both companies are working on drugs that lower an antibody tied to numerous autoimmune conditions.

Via Investor's Business Daily

Immunovant Soars 73% — And Slugs Argenx — As Autoimmune Disease Battle Heats Up ↗

September 26, 2023

Immunovant is hoping to come up with the best drug in its class, lowering a key antibody tied to autoimmune diseases.

Via Investor's Business Daily

Argenx's 28% Surge & Promising Product Propel Investor Confidence

September 25, 2023

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

Via MarketBeat

argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis

September 21, 2023

From argenx SE

Via GlobeNewswire

This New S&P 500 Entrant Leads 5 Stocks Near Buy Points ↗

September 16, 2023

These stocks could lead if the market rallies.

Via Investor's Business Daily

Topics Stocks

$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today ↗

July 31, 2023

Via Benzinga

Is Argenx Stock a Buy Now? ↗

July 31, 2023

Good news keeps rolling in for the biotech.

Via The Motley Fool

argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis

September 15, 2023

From argenx SE

Via GlobeNewswire

argenx to Present at Upcoming Investor Conferences

August 30, 2023

From argenx SE

Via GlobeNewswire

Top AI Stock ANET Leads 5 Stocks Near Buy Points In Tough Market ↗

August 19, 2023

Arista Networks and Dutch biotech Argenx lead this weekend's watch list.

Via Investor's Business Daily

Topics Artificial Intelligence

argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update

July 27, 2023

From argenx SE

Via GlobeNewswire

Earnings Outlook For argenx ↗

July 26, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023 ↗

July 31, 2023

Via Benzinga

< Previous 1 2

...

9 10 11 12 13 14 15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Sports
Entertainment
Local Events
Obituaries
Multimedia
Announcements
e-Edition
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

bentoncourier.com
321 North Market Street
Benton, AR 72018
Phone: 501-315-8228
Email: bcadmin@bentoncourier.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Benton, AR (72018)

Today

Tonight

argenx SE - American Depositary Shares (NQ:ARGX)

All News about argenx SE - American Depositary Shares

Sections

Services

Follow Us